Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in J...
2018年2月1日 - 5:20PM
JCN Newswire (英)
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today
that the primary endpoint was met in a Phase II/III clinical study
on the investigational Parkinson's disease treatment ME2125
(safinamide mesylate, "safinamide") in patients with Parkinson's
disease. Having received the results of the study, Meiji plans to
submit a marketing authorization application for safinamide in
Japan during 2018.
The study was a multicenter, double-blind, placebo-controlled,
randomized, parallel group study to evaluate the efficacy and
safety of two doses of safinamide (50 and 100 mg, once a day for 24
weeks) administered orally as add-on therapy in Japanese patients
with Parkinson's disease with wearing-off phenomenon(1) who are
currently receiving levodopa. The study was conducted by Meiji in
Japan in accordance with the licensing agreement between the two
companies. In this study, the primary endpoint was the change in
mean daily "on" time(2) from baseline to 24 weeks of the treatment
phase.
From the preliminary results of the study, the safinamide group (50
and 100 mg/day, respectively) demonstrated a statistically
significant increase in "on" time compared to the placebo group. In
addition, the four most commonly reported adverse events in the
safinamide groups in the study were nasopharyngitis, dyskinesia,
fall, and contusion.
Under the agreement signed between Eisai and Meiji in March 2017,
Eisai obtained the exclusive rights to safinamide to market in
Japan and to develop and market in Asia(3). Meiji will continue the
clinical trials that it is currently conducting and submit a
marketing authorization application for the drug in Japan.
Meanwhile, Eisai will conduct clinical trials for seeking
regulatory approval, and make the applications in Asia.
Through the development of safinamide, Eisai and Meiji will make
further contributions to address the diversified needs of, and
increase the benefits provided to, Parkinson's disease patients and
their families.
(1) Wearing off phenomenon: As the disease progresses, levodopa's
duration of effect ("on" time) decreases, and Parkinson's disease
symptoms return before the next dose
(2) On time: Period of time in which Parkinson's disease symptoms
are suppressed due to the effect of levodopa
(3) South Korea, Taiwan, Brunei, Cambodia, Laos, Malaysia, the
Philippines, Indonesia, Thailand, Vietnam, Myanmar, Singapore, Hong
Kong, Macao
About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human
health care (hhc) company that discovers, develops and markets
products throughout the world. Eisai focuses its efforts in three
therapeutic areas: integrative neuroscience, including neurology
and psychiatric medicines; integrative oncology, which encompasses
oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of
research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the
worldwide healthcare system. For more information about Eisai Co.,
Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Eisai
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Copyright 2018 JCN Newswire . All rights reserved.